Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Med Pediatr Oncol ; 20(3): 240-2, 1992.
Article in English | MEDLINE | ID: mdl-1374149

ABSTRACT

Myelosuppression is a common sequelae of radiotherapy, occasionally delaying the completion of treatment. In this report, we describe successful reversal of radiation-induced neutropenia in a child receiving craniospinal irradiation by granulocyte colony-stimulating factor (G-CSF). We suggest that G-CSF be considered as supportive care in patients in whom neutropenia develops during radiotherapy.


Subject(s)
Granulocyte Colony-Stimulating Factor/therapeutic use , Neutropenia/drug therapy , Cerebellar Neoplasms/radiotherapy , Humans , Infant , Male , Medulloblastoma/radiotherapy , Neutropenia/etiology , Radiotherapy/adverse effects
2.
J Comput Assist Tomogr ; 16(1): 62-8, 1992.
Article in English | MEDLINE | ID: mdl-1729308

ABSTRACT

Seventeen pediatric patients with posterior fossa brain tumors were studied with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET). The FDG uptake was ranked by two observers, and the results were correlated with tumor histology. Increased FDG uptake was associated with more malignant and aggressive tumor types. Heterogeneity of FDG uptake was associated with previous therapy, including radiation therapy and chemotherapy. 2-[18F]Fluoro-2-deoxy-D-glucose PET will likely be an important adjunct in the management of pediatric posterior fossa tumors, much as in adult patients with brain tumors.


Subject(s)
Brain Neoplasms/diagnostic imaging , Deoxyglucose/analogs & derivatives , Tomography, Emission-Computed , Adolescent , Brain/diagnostic imaging , Child , Child, Preschool , Cranial Fossa, Posterior , Female , Fluorodeoxyglucose F18 , Humans , Male , Tomography, X-Ray Computed
3.
Neurosurgery ; 22(4): 687-90, 1988 Apr.
Article in English | MEDLINE | ID: mdl-2836757

ABSTRACT

Preirradiation chemotherapy is a potentially important component of combined treatment for brain tumors; however, concerns over its side effects and antitumor activity have impeded its evaluation in clinical trials. To determine the feasibility of administering such therapy to children, we assessed the responses of 38 brain tumor patients (median age, 2 years) to 12 weeks of combination chemotherapy given after surgical resection but before irradiation. Transient myelosuppression was noted in all patients, but was not associated with infections or complications of surgical wounds. The ability of the patients to perform activities of daily life, as rated with the Karnofsky performance scale, was either improved (n = 14) or unchanged (n = 18) at the end of the evaluation period. In the remainder of the group, functional deterioration was clearly related to causes other than drug treatment. Prior chemotherapy did not compromise the delivery of radiation except for a brief interruption of spinal irradiation in 3 patients. Objective responses to chemotherapy, defined as a greater than 50% decrease in tumor masses, occurred in 16 of the 31 patients who had subtotal resections; only 6 patients in the entire group showed disease progression during the 12 weeks of drug administration. We conclude that chemotherapy of the type used in this study is well tolerated and produces beneficial effects in children with brain tumors.


Subject(s)
Brain Neoplasms/therapy , Ependymoma/therapy , Glioblastoma/therapy , Medulloblastoma/therapy , Adolescent , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Child , Child, Preschool , Combined Modality Therapy , Ependymoma/drug therapy , Ependymoma/radiotherapy , Ependymoma/surgery , Glioblastoma/drug therapy , Glioblastoma/radiotherapy , Glioblastoma/surgery , Humans , Infant , Medulloblastoma/drug therapy , Medulloblastoma/radiotherapy , Medulloblastoma/surgery , Postoperative Period
SELECTION OF CITATIONS
SEARCH DETAIL